Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin fq on detrusor overactivity in humans

A pilot study

Massimo Lazzeri, Girolamo Cal̀o, Michele Spinelli, Remo Guerrini, Patrizia Beneforti, Sandro Sandri, Alberto Zanollo, Domenico Regoli, Damiano Turini

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: Management of neurogenic incontinence is complex and available treatments are not satisfactory. Nociceptin/orphanin FQ, a recently discovered neuropeptide, has been reported to inhibit the voiding reflex in the rat. These experimental results prompted us to investigate the urodynamic and clinical effects of intravesical instillation of nociceptin/orphanin FQ in humans. Material and Methods: Our study involved 5 normal subjects (group 1) with a mean age of 40.4 years (range 21 to 54) and 9 patients (group 2) 40.4 years (24 to 54). All patients in group 2 presented with detrusor hyperreflexia refractory to standard therapy. They were invited to undergo a filling cystometrogram with saline solution and after 30 minutes, a new one with a solution containing 1 μM. nociceptin/orphanin FQ. The urodynamic parameters that were recorded included bladder capacity, volume threshold for the appearance of detrusor hyperreflexia and maximum bladder pressure. Clinical and urodynamic followup was performed after 15 days. The data were statistically analyzed with 1-way analysis of variance followed by the Dunnett test for multiple comparison considered statistically significant with p

Original languageEnglish
Pages (from-to)2237-2240
Number of pages4
JournalJournal of Urology
Volume166
Issue number6
Publication statusPublished - 2001

Fingerprint

Urodynamics
Abnormal Reflexes
Urinary Bladder
Intravesical Administration
Neuropeptides
Sodium Chloride
Reflex
Analysis of Variance
Pressure
Therapeutics
nociceptin

Keywords

  • Bladder
  • Neuropeptides
  • Urinary incontinence

ASJC Scopus subject areas

  • Urology

Cite this

Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin fq on detrusor overactivity in humans : A pilot study. / Lazzeri, Massimo; Cal̀o, Girolamo; Spinelli, Michele; Guerrini, Remo; Beneforti, Patrizia; Sandri, Sandro; Zanollo, Alberto; Regoli, Domenico; Turini, Damiano.

In: Journal of Urology, Vol. 166, No. 6, 2001, p. 2237-2240.

Research output: Contribution to journalArticle

Lazzeri, M, Cal̀o, G, Spinelli, M, Guerrini, R, Beneforti, P, Sandri, S, Zanollo, A, Regoli, D & Turini, D 2001, 'Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin fq on detrusor overactivity in humans: A pilot study', Journal of Urology, vol. 166, no. 6, pp. 2237-2240.
Lazzeri, Massimo ; Cal̀o, Girolamo ; Spinelli, Michele ; Guerrini, Remo ; Beneforti, Patrizia ; Sandri, Sandro ; Zanollo, Alberto ; Regoli, Domenico ; Turini, Damiano. / Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin fq on detrusor overactivity in humans : A pilot study. In: Journal of Urology. 2001 ; Vol. 166, No. 6. pp. 2237-2240.
@article{bf35c5cd09504ba5989b964fed72c7aa,
title = "Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin fq on detrusor overactivity in humans: A pilot study",
abstract = "Purpose: Management of neurogenic incontinence is complex and available treatments are not satisfactory. Nociceptin/orphanin FQ, a recently discovered neuropeptide, has been reported to inhibit the voiding reflex in the rat. These experimental results prompted us to investigate the urodynamic and clinical effects of intravesical instillation of nociceptin/orphanin FQ in humans. Material and Methods: Our study involved 5 normal subjects (group 1) with a mean age of 40.4 years (range 21 to 54) and 9 patients (group 2) 40.4 years (24 to 54). All patients in group 2 presented with detrusor hyperreflexia refractory to standard therapy. They were invited to undergo a filling cystometrogram with saline solution and after 30 minutes, a new one with a solution containing 1 μM. nociceptin/orphanin FQ. The urodynamic parameters that were recorded included bladder capacity, volume threshold for the appearance of detrusor hyperreflexia and maximum bladder pressure. Clinical and urodynamic followup was performed after 15 days. The data were statistically analyzed with 1-way analysis of variance followed by the Dunnett test for multiple comparison considered statistically significant with p",
keywords = "Bladder, Neuropeptides, Urinary incontinence",
author = "Massimo Lazzeri and Girolamo Cal̀o and Michele Spinelli and Remo Guerrini and Patrizia Beneforti and Sandro Sandri and Alberto Zanollo and Domenico Regoli and Damiano Turini",
year = "2001",
language = "English",
volume = "166",
pages = "2237--2240",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin fq on detrusor overactivity in humans

T2 - A pilot study

AU - Lazzeri, Massimo

AU - Cal̀o, Girolamo

AU - Spinelli, Michele

AU - Guerrini, Remo

AU - Beneforti, Patrizia

AU - Sandri, Sandro

AU - Zanollo, Alberto

AU - Regoli, Domenico

AU - Turini, Damiano

PY - 2001

Y1 - 2001

N2 - Purpose: Management of neurogenic incontinence is complex and available treatments are not satisfactory. Nociceptin/orphanin FQ, a recently discovered neuropeptide, has been reported to inhibit the voiding reflex in the rat. These experimental results prompted us to investigate the urodynamic and clinical effects of intravesical instillation of nociceptin/orphanin FQ in humans. Material and Methods: Our study involved 5 normal subjects (group 1) with a mean age of 40.4 years (range 21 to 54) and 9 patients (group 2) 40.4 years (24 to 54). All patients in group 2 presented with detrusor hyperreflexia refractory to standard therapy. They were invited to undergo a filling cystometrogram with saline solution and after 30 minutes, a new one with a solution containing 1 μM. nociceptin/orphanin FQ. The urodynamic parameters that were recorded included bladder capacity, volume threshold for the appearance of detrusor hyperreflexia and maximum bladder pressure. Clinical and urodynamic followup was performed after 15 days. The data were statistically analyzed with 1-way analysis of variance followed by the Dunnett test for multiple comparison considered statistically significant with p

AB - Purpose: Management of neurogenic incontinence is complex and available treatments are not satisfactory. Nociceptin/orphanin FQ, a recently discovered neuropeptide, has been reported to inhibit the voiding reflex in the rat. These experimental results prompted us to investigate the urodynamic and clinical effects of intravesical instillation of nociceptin/orphanin FQ in humans. Material and Methods: Our study involved 5 normal subjects (group 1) with a mean age of 40.4 years (range 21 to 54) and 9 patients (group 2) 40.4 years (24 to 54). All patients in group 2 presented with detrusor hyperreflexia refractory to standard therapy. They were invited to undergo a filling cystometrogram with saline solution and after 30 minutes, a new one with a solution containing 1 μM. nociceptin/orphanin FQ. The urodynamic parameters that were recorded included bladder capacity, volume threshold for the appearance of detrusor hyperreflexia and maximum bladder pressure. Clinical and urodynamic followup was performed after 15 days. The data were statistically analyzed with 1-way analysis of variance followed by the Dunnett test for multiple comparison considered statistically significant with p

KW - Bladder

KW - Neuropeptides

KW - Urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=0035173911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035173911&partnerID=8YFLogxK

M3 - Article

VL - 166

SP - 2237

EP - 2240

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -